Broich K - Search Results

1

Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value.

Arlett P, Kjaer J, Broich K, Cooke E. Arlett P, et al. Among authors: broich k. Clin Pharmacol Ther. 2022 Jan;111(1):21-23. doi: 10.1002/cpt.2479. Epub 2021 Nov 19. Clin Pharmacol Ther. 2022. PMID: 34797920 Free PMC article. No abstract available.

2

Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?

Eichler HG, Bloechl-Daum B, Broich K, Kyrle PA, Oderkirk J, Rasi G, Santos Ivo R, Schuurman A, Senderovitz T, Slawomirski L, Wenzl M, Paris V. Eichler HG, et al. Among authors: broich k. Clin Pharmacol Ther. 2019 Apr;105(4):912-922. doi: 10.1002/cpt.1226. Epub 2018 Oct 14. Clin Pharmacol Ther. 2019. PMID: 30178490 Free PMC article.

3

COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe.

Szepessy E, Arlett P, Sweeney F, Broich K, Rys AJ. Szepessy E, et al. Among authors: broich k. Lancet Infect Dis. 2022 Mar;22(3):315-316. doi: 10.1016/S1473-3099(22)00061-5. Lancet Infect Dis. 2022. PMID: 35218746 Free PMC article. No abstract available.

4

The European Medicines Agency's strategies to meet the challenges of Alzheimer disease.

Haas M, Mantua V, Haberkamp M, Pani L, Isaac M, Butlen-Ducuing F, Vamvakas S, Broich K. Haas M, et al. Among authors: broich k. Nat Rev Drug Discov. 2015 Apr;14(4):221-2. doi: 10.1038/nrd4585. Nat Rev Drug Discov. 2015. PMID: 25829266

5

Drug Regulation and Pricing--Can Regulators Influence Affordability?

Eichler HG, Hurts H, Broich K, Rasi G. Eichler HG, et al. Among authors: broich k. N Engl J Med. 2016 May 12;374(19):1807-9. doi: 10.1056/NEJMp1601294. N Engl J Med. 2016. PMID: 27168431 No abstract available.

6

The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics.

Enzmann H, Meyer R, Broich K. Enzmann H, et al. Among authors: broich k. Biomark Med. 2016 Dec;10(12):1261-1268. doi: 10.2217/bmm-2016-0233. Epub 2016 Sep 23. Biomark Med. 2016. PMID: 27661101 Free article.

7

Addressing the regulatory and scientific challenges in multiple sclerosis--a statement from the EU regulators.

Balabanov P, Haas M, Elferink A, Bakchine S, Broich K. Balabanov P, et al. Among authors: broich k. Mult Scler. 2014 Sep;20(10):1282-7. doi: 10.1177/1352458514546876. Mult Scler. 2014. PMID: 25160121

8

[Current state of knowledge and developments in the prophylaxis and acute treatment of migraine].

Schriever J, Bühlen M, Broich K. Schriever J, et al. Among authors: broich k. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Aug;57(8):974-82. doi: 10.1007/s00103-014-2000-x. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014. PMID: 25028243 German.

9

[Interplay between marketing authorization and early benefit assessment of drugs].

Beinlich P, Müller-Berghaus J, Sudhop T, Vieths S, Broich K. Beinlich P, et al. Among authors: broich k. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Mar;58(3):227-31. doi: 10.1007/s00103-014-2108-z. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015. PMID: 25566840 German.

10

Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.

Heim HK, Broich K. Heim HK, et al. Among authors: broich k. Thromb Haemost. 2006 Oct;96(4):423-32. Thromb Haemost. 2006. PMID: 17003918

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

149 results

Search Page